Ekkert eitt blóðpróf staðfestir Kawasaki-sjúkdóm. Greiningin byggist á sögu um hita, skoðun, bólgumælingum, stuðningsniðurstöðum rannsóknarprófa og hjartaómun—viðvarandi hiti hjá barni krefst tafarlauss mats, ekki þess að beðið sé eftir öllum dæmigerðu einkennunum.
Helstu niðurstöður
- Greining krefst klínísks mats; ekkert einstakt blóðpróf fyrir Kawasaki-sjúkdóm getur á áreiðanlegan hátt staðfest eða útilokað sjúkdóminn.
- Viðvarandi hiti sem varir í 5 daga krefst tafarlauss mats vegna Kawasaki-sjúkdóms, en barn sem virðist alvarlega veikt þarf fyrr á umönnun að halda.
- Bólgumerki CRP ≥30 mg/L eða ESR ≥40 mm/hour styðja frekara mat samkvæmt leiðbeiningum American Heart Association um ófullkominn Kawasaki-sjúkdóm.
- Ófullkominn Kawasaki-sjúkdómur getur komið fram með aðeins 2–3 dæmigerðum einkennum; ungbörn geta haft langvarandi hita með örfáum sýnilegum einkennum.
- Blóðflögur ≥450 × 10⁹/L eftir 7. veikindadag eru stuðningsniðurstöður; eðlilegur fjöldi blóðflagna fyrstu vikuna útilokar ekki Kawasaki-sjúkdóm.
- Stuðningsniðurstöður eru meðal annars albúmín ≤30 g/L, blóðleysi miðað við aldur, hækkað ALT, WBC ≥15 × 10⁹/L og ≥10 hvít blóðkorn í hverju sjónsviði við mikla stækkun.
- Hjartaómskoðun metur kransæðarnar og hjartastarfsemina; eðlileg snemmmyndataka útilokar ekki Kawasaki-sjúkdóm.
- Tímasetning meðferðar skiptir máli: sjúkrahúsmeðferð felur yfirleitt í sér gjöf immúnóglóbúlíns í æð, helst innan fyrstu 10 veikindadaganna, án þess að bíða eftir að öll einkenni komi fram.
Getur blóðpróf fyrir Kawasaki-sjúkdóm staðfest greininguna?
Ekkert einstakt blóðpróf fyrir Kawasaki-sjúkdóm staðfestir greininguna. Blóðpróf mæla bólgu og viðbrögð líffæra, en læknar bera kennsl á sjúkdóminn út frá hita, niðurstöðum skoðunar og hjartamyndgreiningu; barn með hita í 5 daga þarf tafarlaust mat, jafnvel þótt öll einkennin séu ekki til staðar.
Kawasaki-sjúkdómur er æðabólga í börnum sem getur haft áhrif á kransæðarnar. Í yfirlýsingu American Heart Association frá 2017 er áætlað að kransæðagúlar komi fram í um það bil 25% ómeðhöndlaðra tilfella; sú tala lýsir ómeðhöndluðum sjúkdómi, ekki öllum börnum með langvarandi hita eða hækkað CRP-gildi (McCrindle o.fl., 2017). Flest börn sem fá sjúkdóminn eru yngri en 5 ára, þótt eldri börn geti einnig fengið hann.
Óeðlilegt bólgumerki er vísbending um ónæmissvörun, ekki auðkenni sjúkdóms. CRP-gildi upp á 80 mg/L getur komið fram við Kawasaki-sjúkdóm, bakteríusýkingu eða annað bólguástand, þannig að niðurstaðan ein og sér getur ekki skorið úr um greininguna. Sömuleiðis gæti niðurstaða með aðeins 1 fráviksmerkt gildi vanmetið áhyggjuefni ef sýnið var tekið snemma eða túlkað með hliðsjón af viðmiðunargildum fyrir fullorðna.
Kantesti er gervigreindarblóðprófaagreini sem getur útskýrt hugtök tengd CRP, CBC og lifrarprófum án þess að greina Kawasaki-sjúkdóm. Okkar öryggisráðstafanir við túlkun niðurstaðna hjá börnum útskýrir hvers vegna ekki er hægt að túlka niðurstöður hjá 3 ára barni út frá forsendum fyrir fullorðna. Upplýsingar um stofnunina okkar greinir frá því hver veitir þessa fræðsluþjónustu; viðvarandi hiti krefst samt mats læknis.
Hvenær ætti að meta viðvarandi hita hjá barni?
Barn með hita í 5 daga ætti að fá tafarlaust klínískt mat, þar á meðal mat á því hvort um Kawasaki-sjúkdóm sé að ræða. Leitaðu fyrr eftir aðstoð ef veikindin eru alvarleg, einkenni valda áhyggjum eða um ungt ungabarn er að ræða; viðmiðið um lengd hita í greiningu er ekki fyrirmæli um að vera heima þar til á 5. degi.
Hiti, 38°C eða hærri, hjá ungbarni yngra en 3 mánaða krefst bráðrar læknisskoðunar. Á öllum aldri krefjast öndunarerfiðleikar, óvenjulegur sljóleiki, lítil svörun, útbrot sem fölna ekki við þrýsting, verulegur vökvaskortur eða merki um lélega blóðrás bráðrar meðferðar. Þessi einkenni eru ekki sértæk fyrir Kawasaki-sjúkdóm; einnig þarf að hafa blóðsýkingu og aðra tímanæma sjúkdóma í huga.
Það að hiti lækki tímabundið við paracetamól útilokar ekki Kawasaki-sjúkdóm. Barni getur liðið betur á milli hitatoppa þótt undirliggjandi veikindi haldi áfram, og einkenni geta komið fram á mismunandi dögum. Skráðu hvenær hitinn byrjaði, raunverulegar hitamælingar, lyf, þvagútskilnað og breytingar á augum, vörum, höndum eða fótum—ekki aðeins hvort hitamælirinn sýndi eðlilegt gildi einu sinni.
Ungbörn yngri en 6 mánaða geta verið með langvarandi hita án hins dæmigerða mynsturs með útbrotum og rauðum augum. Óútskýrður hiti sem varir í að minnsta kosti 7 daga er viðurkennd ástæða til að meta hvort um ófullkominn sjúkdóm sé að ræða samkvæmt ferli AHA. Okkar leiðbeiningar um undirbúning sýna nýtast við fyrirhugaðar rannsóknir, en veikt barn ætti aldrei að þurfa að bíða eftir föstu, hentugum tíma eða fullum gátlista yfir einkenni.
Hvernig er Kawasaki-sjúkdómur greindur út frá klínískum einkennum?
Klassískur Kawasaki-sjúkdómur er yfirleitt greindur út frá hita sem varir í að minnsta kosti 5 daga ásamt að minnsta kosti 4 af 5 helstu klínísku einkennunum. Clinicians can diagnose some strongly characteristic cases earlier; neither the fever count nor the symptom count replaces clinical judgment or urgent evaluation.
The 5 principal features are bilateral non-purulent conjunctival redness, mouth changes, a polymorphous rash, extremity changes, and cervical lymphadenopathy. Mouth changes include red or cracked lips and a strawberry tongue; hand and foot changes include redness or swelling. The lymph-node criterion is usually a cervical node at least 1.5 cm across, often on one side.
The clinical features do not have to occur simultaneously. A photograph of a rash from illness day 3 may remain diagnostically useful when the skin looks different on day 6, and a previous episode of swollen hands should not disappear from the history because swelling has improved. Peeling around the fingertips often occurs during weeks 2–3, too late to use as a reason to delay assessment.
Certain findings point toward alternative explanations rather than strengthening the classic Kawasaki pattern. Purulent eye discharge, prominent exudative tonsillitis, or discrete mouth ulcers deserve separate consideration, although no single finding resolves every case. Our laboratory marker reference guide explains test terminology; it cannot substitute for examining the 5 clinical feature groups or arranging appropriate imaging.
Hvernig styðja rannsóknarstofupróf greiningu á ófullkomnum Kawasaki-sjúkdómi?
Incomplete Kawasaki disease means a child has fewer classic features but enough clinical, laboratory, or echocardiographic evidence to warrant diagnosis and treatment. The AHA evaluation pathway considers children with fever for at least 5 days and 2–3 features, and certain infants with unexplained fever for at least 7 days.
CRP ≥30 mg/L or ESR ≥40 mm/hour supports proceeding through the AHA incomplete-disease evaluation pathway. When inflammation reaches either threshold, clinicians assess echocardiography and supplementary laboratory criteria rather than waiting for another visible symptom. The thresholds are decision supports for a compatible illness—not proof that Kawasaki disease is the cause (McCrindle et al., 2017).
The 6 supplementary laboratory criteria are albumin ≤30 g/L, anemia for age, elevated ALT, WBC ≥15 × 10⁹/L, platelets ≥450 × 10⁹/L after day 7, and urine ≥10 white cells per high-power field. In the appropriate clinical setting, at least 3 supplementary criteria or a positive echocardiogram can support treatment through the pathway. These are not independent points to count without reviewing competing diagnoses.
Fewer than 3 supplementary criteria does not create a permanent rule-out result. Persistent fever may require repeated examination, repeat laboratory testing, and imaging, particularly if the first evaluation occurred early. Systemic juvenile idiopathic arthritis is one possible alternative; our childhood arthritis laboratory guide explains why shared inflammatory findings do not make these conditions interchangeable.
Hvað merkja niðurstöður CRP og ESR við Kawasaki-sjúkdóm?
CRP and ESR support Kawasaki evaluation by showing systemic inflammation, but neither identifies its cause. In the AHA incomplete-disease pathway, CRP ≥30 mg/L or ESR ≥40 mm/hour is a threshold for further assessment, not a severity scale or a stand-alone indication for treatment.
CRP of 3 mg/dL equals 30 mg/L. This 10-fold unit difference can make identical results appear very different when families compare reports from different laboratories, while common CRP reference limits are around 5 mg/L but vary by method. Our samanburður á WBC og CRP explains why a high CRP and a less impressive white-cell count can coexist.
ESR is influenced by factors beyond the immediate inflammatory response, including anemia and circulating proteins. A result of 45 mm/hour is not directly comparable to CRP of 45 mg/L; the tests measure different processes and have different kinetics. When both markers are below the pathway thresholds, Kawasaki disease becomes less likely, but an early sample or a concerning clinical course still requires judgment.
High-sensitivity CRP measures the same protein as conventional CRP, but adult cardiovascular-risk categories do not apply to a febrile child. A value of 30 mg/L during illness should not be interpreted using an adult 1–3 mg/L cardiovascular-risk framework. Our hs-CRP interpretation guide explains that distinction; for acute pediatric illness, the clinical question is inflammation and its cause.
| Styrkur | Bil | Merking |
|---|---|---|
| Algeng viðmiðunarmörk fyrir CRP | Often <5 mg/L; laboratory-specific | A reference interval, not a Kawasaki exclusion threshold; early disease may require reassessment. |
| Incomplete-disease CRP trigger | ≥30 mg/L, equivalent to ≥3 mg/dL | Supports further AHA pathway evaluation when fever and clinical history are compatible. |
| Common ESR reference interval | Often approximately 0–20 mm/hour; age- and method-dependent | Use the reporting laboratory's pediatric interval; ESR is affected by anemia and proteins. |
| Incomplete-disease ESR trigger | ≥40 mm/hour | Supports further evaluation; neither confirms Kawasaki disease nor defines an emergency by itself. |
Hvaða niðurstöður CBC styðja Kawasaki-sjúkdóm?
Kawasaki disease lab findings on a CBC can include neutrophil-predominant leukocytosis, anemia for age, and a later rise in platelets. WBC ≥15 × 10⁹/L and platelets ≥450 × 10⁹/L after day 7 are supplementary incomplete-disease criteria, but the illness day changes their meaning.
Platelets often rise during the second week rather than at the start of fever. A platelet count of 280 × 10⁹/L on illness day 4 therefore does not exclude Kawasaki disease, and waiting for thrombocytosis can delay care. Conversely, a count of 520 × 10⁹/L after day 7 supports the pattern but can also occur during recovery from other inflammatory illnesses.
Anemia in the incomplete-disease criteria is defined against the child's age, not a universal hemoglobin cutoff. For a hypothetical 3-year-old, hemoglobin of 9.8 g/dL would generally be low, but the cause could include inflammation, pre-existing iron deficiency, or both. WBC also needs age-specific context; our leiðbeiningar um viðmiðunarmörk daufkyrninga explains why pediatric differential counts differ from adult ones.
Low platelets can occur in severe Kawasaki presentations and should not be treated as reassuring. A febrile child with platelets of 90 × 10⁹/L, poor circulation, or worsening organ function needs urgent assessment for shock, sepsis, consumption, or macrophage activation. Platelet size indices and neutrophil-to-lymphocyte ratios remain contextual findings; they are not substitutes for the 6 established supplementary criteria.
Hvers vegna breytast albúmín og lifrarpróf?
Low albumin and elevated ALT can support incomplete Kawasaki disease because systemic inflammation affects protein distribution and liver function. Albumin ≤30 g/L is a defined supplementary criterion, while ALT is judged against the laboratory's pediatric upper reference limit rather than one universal Kawasaki cutoff.
Albumin of 3.0 g/dL equals 30 g/L. During acute illness, a low result can reflect reduced synthesis, increased vascular permeability, dilution, or protein loss—not simply poor dietary protein intake. Our leiðbeiningar um greiningu á sermisprótínum explains these mechanisms; nutritional advice alone would miss the clinical significance of low albumin combined with persistent fever.
An ALT result above the pediatric upper limit counts as supporting evidence, but its magnitude does not diagnose Kawasaki disease. For example, a hypothetical child with albumin 28 g/L and ALT 72 IU/L may meet 2 supplementary criteria if that ALT exceeds the local limit. The same combination can arise from other illnesses or medication effects, as our hugtakahandbók um ALT útskýrir.
Kantesti is an AI blood test interpretation platform that can explain why albumin 28 g/L and ALT 72 IU/L require clinical context. Okkar AI tækni útskýring describes the interpretation workflow, not a validated Kawasaki diagnostic test. Growing children can also have relatively high alkaline phosphatase from bone activity; that finding is not interchangeable with the ALT criterion.
Geta þvagpróf og natríum stutt matið?
Urine white cells can support incomplete Kawasaki evaluation, while electrolyte changes help assess illness severity and alternative causes. Urine ≥10 white cells per high-power field is a supplementary criterion; low sodium is a possible associated finding but is not one of the 6 AHA supplementary laboratory criteria.
Sterile pyuria means urine white cells are present without a demonstrated bacterial cause on an appropriately collected culture. Kawasaki disease can produce this pattern, but a child with urine white cells still needs assessment for urinary infection. A urine dipstick alone cannot establish sterile pyuria; our leiðbeiningum okkar um túlkun þvagsets distinguishes microscopy findings from dipstick screening results.
A report of 10 white cells per high-power field cannot be directly equated with an automated result of 10 cells/µL. Instruments, specimen preparation, and counting methods differ, so clinicians may need the laboratory's conversion or interpretive guidance. Collection quality also matters: contamination can introduce cells, whereas prior antibiotics can reduce culture yield without explaining the entire fever pattern.
Serum sodium below 135 mmol/L is generally classified as hyponatremia, but its cause must be assessed separately. Acute inflammation, fluid intake, gastrointestinal losses, and altered water regulation can all contribute; the number is not a Kawasaki confirmation test. Our leiðbeining um efnaskiptamynstur explains why sodium 130 mmol/L with neurological symptoms is a different problem from an isolated mildly low value.
Hverju bætir hjartaómun við greininguna?
Echocardiography assesses coronary artery dimensions, heart function, and other cardiac findings that blood tests cannot show. A coronary artery Z-score ≥2.5 can support Kawasaki diagnosis in the incomplete-disease pathway, but a normal early echocardiogram does not exclude the illness or justify delaying indicated treatment.
A coronary Z-score compares artery size with the expected size for a child's body surface area. A raw measurement such as 3 mm therefore has different implications in a small infant and a much larger child. The 2024 AHA statement emphasizes coronary assessment and risk-based management; the number should be interpreted with the measurement method and clinical setting (Jone et al., 2024).
A positive echocardiogram in the AHA incomplete-disease pathway can include a coronary aneurysm or a qualifying coronary Z-score. It can also involve at least 3 suggestive findings: decreased left-ventricular function, mitral regurgitation, pericardial effusion, or left anterior descending/right coronary Z-scores of 2 to less than 2.5. This is specialist image interpretation, not a checklist parents should apply to a brief scan summary.
Troponin and BNP or NT-proBNP may help evaluate cardiac involvement but do not replace echocardiography. A normal troponin on 1 sample cannot show that the coronary arteries are unaffected, and an elevated BNP can have several explanations. Our myocarditis laboratory guide explains the distinction between evidence of heart-muscle involvement and the separate question of coronary artery changes.
Hvernig greina læknar Kawasaki-sjúkdóm frá sjúkdómum sem líkjast honum?
Clinicians distinguish Kawasaki disease from other causes of fever by combining the illness timeline, examination, targeted infection testing, laboratory patterns, and heart imaging. MIS-C, bacterial infections, adenovirus, scarlet fever, and systemic inflammatory disorders can overlap; a CRP result of 80 mg/L cannot separate them reliably.
MIS-C often follows SARS-CoV-2 infection by approximately 2–6 weeks and frequently affects older children than classic Kawasaki disease. Prominent gastrointestinal symptoms, shock, lymphopenia, relatively low platelets, and ventricular dysfunction may favor MIS-C, but overlap is substantial. A positive SARS-CoV-2 antibody result alone does not settle the distinction because previous infection or vaccination can affect interpretation.
Procalcitonin can rise in Kawasaki disease and should not automatically be treated as proof of a bacterial cause. Clinicians assess cultures, examination, organ function, and the broader trajectory before deciding what an elevated result means. Our leiðbeiningar um túlkun prókalsítóníns explains why 1 biomarker cannot safely decide between sepsis, Kawasaki disease, or another inflammatory syndrome.
Finding a respiratory virus does not necessarily exclude coexisting Kawasaki disease. A hypothetical child with 6 days of fever, characteristic mouth changes, swollen feet, and an adenovirus-positive swab still needs a complete clinical assessment rather than automatic dismissal of the other findings. Travel, medication exposure, urinary symptoms, and recurrent fever patterns guide additional testing; there is no universal panel that rules out every mimic.
Hvers vegna breyta veikindadagur og endurtekin próf myndinni?
Kawasaki laboratory findings evolve, so the illness day and treatment history are part of every result's meaning. A normal platelet count early in the first week can become elevated later, while intravenous immunoglobulin can raise ESR independently of ongoing inflammation and make post-treatment ESR misleading.
A changing CBC can strengthen suspicion without making the first sample wrong. For example, a hypothetical child might have WBC 13 × 10⁹/L and platelets 280 × 10⁹/L on day 4, then platelets 480 × 10⁹/L and albumin 29 g/L on day 7. Clinicians should not postpone a concerning assessment until those later findings appear; our leiðarvísir um tímabil rannsóknarstofu explains evolving results.
ESR should not be used as the main measure of response after intravenous immunoglobulin. The infused proteins can increase sedimentation, so an ESR of 70 mm/hour after treatment does not necessarily mean treatment failure. Fever, clinical recovery, CRP trends, and cardiac assessment are more useful in context; the 2017 AHA statement specifically describes this post-infusion limitation (McCrindle et al., 2017).
Kantesti can help explain serial reports, but a trend graph cannot determine whether a child needs retreatment. Record the sample date, illness day, infusion completion time, and laboratory units alongside each value; comparing 2 results without that information can produce a false impression of deterioration. Immunoglobulin can also complicate some antibody tests through passive antibody transfer, so the treating team needs the infusion history.
Hvers vegna ætti meðferð ekki að bíða eftir öllum einkennum?
Treatment should begin promptly when Kawasaki disease is diagnosed, including incomplete disease, rather than waiting for every classic feature. Standard initial hospital treatment includes intravenous immunoglobulin at 2 g/kg, generally within the first 10 illness days; later treatment may still be indicated when fever or inflammation persists.
The 10-day treatment window is a target for timely care, not a reason to delay until day 10. The ACR/Vasculitis Foundation guideline recommends prompt treatment of incomplete Kawasaki disease once diagnosed, rather than waiting for the child to satisfy classic criteria (Gorelik et al., 2022). For a hypothetical 12-kg child, 2 g/kg represents 24 g of immunoglobulin administered under hospital supervision.
Aspirin treatment in Kawasaki disease requires a pediatric specialist's prescription and monitoring. Acute regimens vary internationally, including 30–50 or 80–100 mg/kg/day, followed in many cases by antiplatelet dosing of 3–5 mg/kg/day; families should not start, stop, or calculate treatment themselves. Our aspirin toxicity guidance explains why a prescribed Kawasaki regimen is not ordinary home fever treatment.
Approximately 10–20% of patients have persistent or recurrent fever after initial immunoglobulin treatment. Fever at least 36 hours after completion of the infusion is a commonly used threshold for IVIG resistance, after other causes are considered. Additional treatment may include corticosteroids or other specialist therapies; infants younger than 6 months and children with coronary Z-scores ≥2.5 can need particular attention, but risk scores do not perform equally across populations.
Eftirfylgni
Improving CRP and CBC results do not prove that coronary artery risk has resolved. Follow-up is based on clinical recovery and echocardiographic findings, including the largest coronary Z-score recorded; children with coronary aneurysms need a different surveillance plan from children whose coronary studies remain normal.
Uncomplicated follow-up often includes echocardiography around 1–2 weeks and 4–6 weeks after treatment, but the schedule is individualized. The 2024 AHA statement supports risk-based assessment, and normal early studies can affect whether further routine imaging adds value (Jone et al., 2024). Persistent coronary changes, poor visualization, recurrent symptoms, or an abnormal initial study can require a different timetable.
A platelet count that remains elevated during recovery is not, by itself, proof of treatment failure. A hypothetical count of 600 × 10⁹/L in week 2 may fit the expected illness phase even when fever has stopped and CRP is falling, but symptoms and cardiac findings still govern management. Our eftirspítalalabprófunarbreytingar guide explains why normalization is not simultaneous across all markers.
High-dose immunoglobulin can affect the timing of certain live vaccines. After IVIG 2 g/kg, measles- and varicella-containing vaccines are commonly deferred for 11 months under immunization guidance, with exceptions assessed by the child's team and local schedule. Ask for a written plan covering vaccines, medicines, activity, repeat imaging, and which symptoms require reassessment; coronary follow-up should not be replaced by an apparently reassuring laboratory report.
Hvernig má nota skýringar frá gervigreind á öruggan hátt meðan á mati stendur?
AI explanations can help families understand laboratory language, but they cannot confirm Kawasaki disease, assess a child's circulation, or interpret coronary imaging independently. With fever lasting 5 days—or concerning symptoms sooner—clinical assessment takes priority over uploading reports, comparing reference ranges, or obtaining another automated interpretation.
Kantesti is an AI lab test interpretation service that can explain what CRP 30 mg/L or platelets 450 × 10⁹/L mean in a report. Those numbers are not sufficient to decide whether a child has Kawasaki disease, and an explanation cannot replace documenting illness day, examination findings, or an echocardiogram. Our meginreglur um ábyrga notkun gervigreindar describe why interpretation must remain separate from urgent pediatric decision-making.
A useful review packet combines at least 3 types of information: the fever timeline, complete laboratory reports, and the treating team's assessment. Preserve units, pediatric reference intervals, medication dates, and imaging conclusions rather than sharing only red flags or screenshots of isolated values. Our medical validation documentation describes evaluation standards and limitations; technical performance should not be read as condition-specific proof of diagnostic safety.
Kantesti's research publications listed below describe platform evaluation and aggregate report analysis, not a Kawasaki diagnostic assay. The Clinical Validation Framework v2.0 and Global Health Report 2026 are hosted on Zenodo, and their DOI identifiers establish persistent records rather than peer-review status. Neither publication should be interpreted as establishing sensitivity or specificity for incomplete Kawasaki disease; clinical recommendations here rely on the 2017 and 2024 AHA statements and the ACR/Vasculitis Foundation guideline.
Algengar spurningar
0 Er til blóðpróf sem staðfestir Kawasaki-sjúkdóm?
Ekkert einstakt blóðpróf staðfestir Kawasaki-sjúkdóm. Læknar leggja saman upplýsingar um hitaferil, niðurstöður skoðunar, bólgumæla, viðbótarniðurstöður rannsóknarstofuprófa og hjartaómun. CRP ≥30 mg/L eða ESR ≥40 mm/hour styður frekara mat samkvæmt leiðbeiningum AHA um ófullkominn sjúkdóm en greinir ekki orsök bólgunnar. Eðlileg niðurstaða úr einu prófi, einkum snemma í veikindunum, getur ekki útilokað sjúkdóminn með öryggi.
Getur barn verið með Kawasaki-sjúkdóm án þess að hafa öll einkennin?
0 AHA-leiðbeiningarnar ná til barna með hita í að minnsta kosti 5 daga og 2–3 einkenni, auk ákveðinna ungbarna með óútskýrðan hita í að minnsta kosti 7 daga. Barn getur verið með ófullkominn Kawasaki-sjúkdóm án allra 5 helstu klínísku einkenna. Frávik sem styðja greiningu í rannsóknarniðurstöðum eða kransæðafundum geta réttlætt greiningu og meðferð. Fjölskyldur ættu að leita tafarlaust mats í stað þess að bíða eftir að húðflögnun eða önnur einkenni komi fram.
Hvaða blóðniðurstöður eru algengar við Kawasaki-sjúkdóm?
Algengar niðurstöður rannsókna hjá fólki með Kawasaki-sjúkdóm eru hækkað CRP eða ESR, aukinn fjöldi hvítra blóðkorna, blóðleysi miðað við aldur, lágt albúmín, hækkað ALT og síðbúin hækkun á blóðflögum. Viðmiðunarmörk fyrir viðbótarrannsóknir við ófullkominn sjúkdóm eru albúmín ≤30 g/L, WBC ≥15 × 10⁹/L og blóðflögur ≥450 × 10⁹/L eftir 7. dag. Þessar niðurstöður eru ekki sértækar fyrir Kawasaki-sjúkdóm og verður að túlka þær með hliðsjón af skoðuninni og framvindu veikindanna. Hvít blóðkorn í þvagi geta einnig stutt við matið, þótt það sé niðurstaða úr þvagrannsókn en ekki blóðrannsókn.
Útiloka eðlileg blóðflögugildi eða eðlilegt hjartaómunarrannsókn Kawasaki-sjúkdóm?
0 Venjulegur fjöldi blóðflagna fyrstu vikuna og eðlileg snemmbúin hjartaómskoðun útiloka ekki Kawasaki-sjúkdóm. Blóðflögum fjölgar oft á annarri vikunni og breytingar á kransæðum sjást hugsanlega ekki við fyrstu skoðun. Blóðflagnafjöldi undir 450 × 10⁹/L snemma í veikindunum útilokar því ekki greininguna. Viðvarandi hiti eða klínískt mynstur sem vekur áhyggjur getur kallað á endurmat án þess að fresta meðferð þegar hún á við.
How long should a child's fever last before seeking help?
0. Barn með hita sem hefur varað í 5 daga ætti að fara í klínískt mat án tafar, en alvarleg einkenni krefjast þess að leitað sé fyrr til heilbrigðisþjónustu. Hiti sem er 38°C eða hærri hjá ungbarni yngra en 3 mánaða krefst bráðs læknismats. Öndunarerfiðleikar, skert viðbragð, útbrot sem fölna ekki við þrýsting, vökvaskortur eða léleg blóðrás krefjast bráðrar eða neyðarþjónustu, óháð því hve lengi hitinn hefur varað. Kawasaki-viðmiðið um 5 daga er ekki fyrirmæli um að bíða.
Hvers vegna er ESR enn hátt eftir meðferð við Kawasaki-sjúkdómi?
ESR getur haldist hátt eða hækkað eftir gjöf immúnóglóbúlíns í æð vegna þess að innrenndu próteinin hafa áhrif á sökk. ESR-gildi upp á 70 mm/klst. eftir meðferð staðfestir því ekki eitt og sér að meðferð hafi brugðist. Læknar meta hita, klínískan bata, þróun CRP og niðurstöður hjartarannsókna í stað þess að reiða sig á ESR eftir innrennsli. Viðvarandi eða endurtekinn hiti að minnsta kosti 36 klukkustundum eftir að innrennsli lýkur krefst endurmats hjá meðferðarteyminu.
Fáðu útskýringar á niðurstöðum blóðrannsókna
Hladdu upp rannsóknarskýrslunni þinni og AI Kantesti útskýrir hvert lífmerki á mannamáli á nokkrum sekúndum. Yfir 2 milljónir manna um allan heim nota þjónustuna.
Heimildir
- Klein, T., Mitchell, S., & Weber, H. (2026). Klínísk sannprófunarviðmið v2.0 (læknisfræðileg sannprófunarsíða). Kantesti AI Medical Research. DOI
- Klein, T., Mitchell, S., & Weber, H. (2026). AI blóðprófunargreinir: 2,5M prófanir greindar | Global Health Report 2026. Kantesti AI Medical Research. DOI
- McCrindle BW et al. (2017). Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation. DOI PubMed
- Jone PN et al. (2024). Update on Diagnosis and Management of Kawasaki Disease: A Scientific Statement From the American Heart Association. Circulation.
- Gorelik M et al. (2022). 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease. Arthritis & Rheumatology.
- 2M+Greindar rannsóknir
- 127+Lönd
- 100+Tungumál
Um læknateymið
E-E-A-T traustmerki
Reynsla
Læknastýrð klínísk yfirferð á vinnuferlum við túlkun rannsóknarniðurstaðna.
Sérþekking
Áhersla á rannsóknarstofulækningar: hvernig lífmarkarar hegða sér í klínísku samhengi.
Yfirvald
Dr. Thomas Klein fór yfir efnið læknisfræðilega, með framlagi frá Dr. Sarah Mitchell og Prof. Dr. Hans Weber.
Traustleiki
Rökstudd túlkun byggð á gögnum með skýrum eftirfylgnileiðum til að draga úr ávörun.
Fyrirvari um læknisfræðilegt efni
Þessi grein er eingöngu til fræðslu og felur ekki í sér læknisráðgjöf. Leitaðu alltaf til hæfs heilbrigðisstarfsmanns vegna ákvarðana um greiningu og meðferð.
Gefið út · Hafðu samband við ritstjórnarteymið
Gefið út af Kantesti Ltd, skráðu í Englandi og Wales, fyrirtækisnúmer. 17090423, London, Bretlandi.
